Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Facilitating physiologic self-regeneration: a step beyond islet cell replacement.

Pleunie P M Rood1, Rita Bottino, A N Balamurugan

  • 1Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pennsylvania, USA.

Pharmaceutical Research
|December 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Silicone rubber membrane devices permit islet culture at high density without adverse effects.

Frontiers in bioengineering and biotechnology·2024
Same author

What Have We Learned From In Vitro Studies About Pig-to-primate Organ Transplantation?

Transplantation·2022
Same author

Cardiac xenotransplantation: from concept to clinic.

Cardiovascular research·2022
Same author

Patient informed consent for a clinical trial of gene-edited pig kidney transplantation: A representative consent form.

Xenotransplantation·2022
Same author

Kidney xenotransplantation: Future clinical reality or science fiction?

Nursing & health sciences·2022
Same author

What is the clinical relevance of deviant serum calcium and phosphate levels after pig-to-primate kidney xenotransplantation?

Xenotransplantation·2022
Same journal

Osmolyte-Based Formulations for Enhanced Thermal Stability of mRNA Drug Substance: A Systematic Screening and Optimization Study.

Pharmaceutical research·2026
Same journal

Design, Synthesis and Characterization of Anti-CTLA4 Peptide Conjugated Gemcitabine Prodrug Nanoparticles for Targeted Lung Cancer Chemoimmunotherapy.

Pharmaceutical research·2026
Same journal

Leveraging Carnitine-functionalized Lipid Nanocarrier based Targeted Delivery of A1874 PROTAC for Glioblastoma.

Pharmaceutical research·2026
Same journal

Impact of Febrile State on Vancomycin Clearance in Pediatric Patients: Insights From Population Pharmacokinetic Modeling.

Pharmaceutical research·2026
Same journal

Sustained Intra-Articular Delivery of Triple Therapeutics Using a Phase-Transition Phospholipid-Based Gel for Effective Treatment of Gouty Arthritis.

Pharmaceutical research·2026
Same journal

Spray Dried Lysozyme Microspheres: Morphological Evolution and Enzymatic Activity Retention.

Pharmaceutical research·2026
See all related articles

Type 1 diabetes (T1D) involves autoimmune destruction of insulin-producing beta cells. Abrogating autoimmunity may allow the pancreas to regenerate, potentially restoring insulin production and offering a new therapy.

Area of Science:

  • Immunology
  • Endocrinology
  • Regenerative Medicine

Background:

  • Type 1 diabetes (T1D) is an autoimmune disease causing beta cell destruction, often diagnosed in childhood.
  • Current treatments like pancreas transplantation are limited by donor scarcity and immunosuppression toxicity.
  • Beta cells possess regenerative capacity, but autoimmune processes and hyperglycemia hinder this in T1D.

Purpose of the Study:

  • To explore the potential of regenerating a patient's own endocrine cells by addressing the autoimmune component of T1D.
  • To investigate if abrogating autoimmunity can restore endogenous insulin production in T1D.

Main Methods:

  • Review of existing evidence on pancreatic islet cell regeneration and autoimmune disease mechanisms.
  • Analysis of the physiological regenerative capacity of the endocrine pancreas.

Related Experiment Videos

  • Conceptual framework for developing autoimmunity-obliterating protocols.

    • Main Results:

    • The endocrine pancreas has inherent regenerative capabilities.
    • Autoimmunity is a key factor preventing beta cell regeneration in T1D.
    • Eliminating autoimmunity may enable the restoration of beta cell function.

    Conclusions:

    • Targeting and eliminating autoimmunity is a promising therapeutic strategy for T1D.
    • Regenerating the patient's own endocrine cells could offer a novel treatment for T1D.
    • Developing clinically translatable protocols to induce an autoimmunity-free status is crucial.